Heart failure in 2010.
The Heart Failure Congress 2010 in Berlin presented the latest trials and trends in the medical and mechanical therapy of heart failure in the presence of impaired or preserved left ventricular ejection fraction. It covered all aspects of heart failure from epidemiology through basic and translational science to prevention. The congress highlighted new drugs, novel biomarkers, updated trials, the role of imaging in risk stratification and the importance of telecare in the reduction of heart failure readmission.
El-Menyar
Ayman
A
Hamad General Hospital, Cardiology Department, PO Box 3050, Doha, Qatar. elmenyar@yahoo.com
AlMahmeed
Wael
W
D065092:Antidiuretic Hormone Receptor Antagonists; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D024722:Cardiac Myosins / Q000502:physiology; D002316:Cardiotonic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D020536:Enzyme Activators / Q000627:therapeutic use; D006162:Guanylate Cyclase / Q000502:physiology; D006333:Heart Failure / Q000175:diagnosis* / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D011379:Prognosis; D018570:Risk Assessment
D065092:Antidiuretic Hormone Receptor Antagonists; D002121:Calcium Channel Blockers; D002316:Cardiotonic Agents; D020536:Enzyme Activators; D024722:Cardiac Myosins; D006162:Guanylate Cyclase